A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke
NEJM 382:9-19,81, Amarenco, P.,et al, 2020
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
NEJM 366:1914-1922;, Davis, S.M. & Donnan, G.A., 2012
The "Million Hearts" Initiative - Preventing Heart Attacks and Strokes
NEJM 365:e27, Frieden, T.R.,et al, 2011
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009
Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009
Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Stroke 39:2444-2448, Goldstein,L.B.,et al., 2008
Expanding Indications for Statins in Cerebral Ischemia
Arch Neurol 62:67-72,23, Ovbiagele,B.,et al, 2005
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
Pravastatin Therapy and The Risk of Stroke
NEJM 343:317-326, White,H.D. et al, 2000
Peripheral Neuropathy with Bezafibrate
BMJ 309:929, Ellis,C.J.,et al, 1994
HMG-CoA Reductase Inhibitor Therapy and Peripheral Neuropathy
Ann Int Med 120:970, Jacobs,M.B., 1994
Platelet-Inhibiting Drugs in the Prevention of Clinical Thrombotic Disease
NEJM 293:174, Genton,E.,et al, 1975
The Treatment of Cerebrovascular Disease with Clofibrate
VA Cooperative Study Group, Stroke 4:6841973., , 1973
Clofibrate for the Treatment of Occlusive CVD-Correspondence
NEJM 287:671, Hirsch,S.,et al, 1972